Tuberculosis (TB)

Sixth meeting of the Working Group on MDR-TB
Tbilisi, Georgia, 20-22 September 2007

SUMMARIES, REACTIONS AND DISCUSSIONS

RELATED LINKS

Interviews carried out by Glenn Thomas (WHO Geneva)

Dr E. Jaramillo, WHO Stop TB focal officer for Drug-Resistant TB

Day 1:
Dr Ernesto Jaramillo
WHO Stop TB focal officer for Drug-Resistant TB
(WHO Geneva)




Dr T. Tupasi, Outgoing Chair of the Stop TB Partnership's MDR-TB Working Group (Philippines)

Day 2:
Dr Thelma Tupasi
Outgoing Chair of the Stop TB Partnership's MDR-TB Working Group
(Philippines)




Dr K. Weyer, Member of the Green Light Committee (South Africa)

Day 3:
Dr Karin Weyer
Member of the Green Light Committee
(South Africa)




Dr M. Kimerling, Professor of Medicine, University of Alabama at Birmingham (USA) and Dr K. Lambregts, KNCV (Netherlands)

Meeting Overview:
Dr Michael Kimerling, Professor of Medicine, University of Alabama at Birmingham (USA) and Dr Kitty Lambregts, KNCV (Netherlands)




Focus issues

Dr W. Jakubowiak (WHO Russia) and Dr Margaret Dalcolmo (Brazil)

TB and infection control
WHO headquarters will host a meeting to address the challenges around implementing infection control TB (22-23 October). Fostering sound infection control measures to avoid MDR-TB and XDR-TB transmission to protect patients, health workers, other working in congregate settings and the broader community, especially in high HIV prevalence settings, is a key objective in the global response plan.

Attending the meeting in Geneva will be Dr Wieslaw Jakubowiak (WHO Russia) and Dr Margaret Dalcolmo (Brazil). Interviewed in Tbilisi, they described their country experiences and the main challenges to ensuring strong and effective infection control.

Drs Keshavjee (USA) and Mirzayev (WHO Geneva)

The Green Light Committee
The Green Light Committee (GLC) has played a pivotal role in strengthening MDR-TB programmes since its conception in 2000.

Dr Fuad Mirzayev (WHO Geneva) and the new Chair of the GLC, Dr Salmaan Keshavjee, (USA) discuss the strategic 'way forward' for the GLC to ensuring the revised MDR-TB patient targets are achieved. Dr Salmaan Keshavjee first began by clarifying the role of the GLC.

Share